By Josh White
Date: Tuesday 31 Oct 2017
LONDON (ShareCast) - (ShareCast News) - Hutchison China MediTech - known as Chi‑Med - has initiated 'FRUTIGA', a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol) for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China.
The AIM-traded company said fruquintinib is a "highly selective and potent" oral inhibitor of vascular endothelial growth factor receptors 1, 2 and 3.
It said the randomised, double-blind, placebo-controlled, multicentre trial was being conducted in patients with advanced gastric cancer who had progressed after first-line standard chemotherapy.
Advanced gastric cancer was described by the company's board as a "major medical need", particularly in Asian populations, with limited treatment options for patients who have failed first-line standard chemotherapy with 5-fluorouracil and platinum doublets.
For gastric cancer, there are approximately 679,100 new cases and 498,000 deaths in China each year.
"Fruquintinib was designed to be a highly selective inhibitor of VEGFR 1, 2 and 3, which has shown the potential ability to combine with chemotherapy - a novel approach in the treatment of advanced gastric cancer," said Chi-Med chief executive Christian Hogg.
"With fruquintinib's new drug application in third-line colorectal cancer under review and its Phase III trial in third-line non-small cell lung cancer nearing full enrollment, we are excited to now also enter the final phase of development in second-line gastric cancer, a very large indication in which there is significant patient need for new treatment options in China."
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 320.00p |
Change Today | -4.00p |
% Change | -1.23 % |
52 Week High | 352.00 |
52 Week Low | 173.60 |
Volume | 9,563 |
Shares Issued | 871.26m |
Market Cap | £2,788.02m |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
11:49 | 4,280 @ 320.00p |
11:48 | 2,867 @ 320.12p |
10:05 | 1,562 @ 320.12p |
10:04 | 1 @ 320.01p |
09:44 | 157 @ 320.40p |
You are here: research